Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on September 25, 2015. The report addresses corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
Management Commentary and Corporate Actions
- Item 5.02: Election of Director.
- Effective September 25, 2015, the Board of Directors appointed Dr. Ben Wu to serve as a director.
- Dr. Wu's term will expire until his successor is duly elected.
- Dr. Ben Wu, M.D., is a founder of the company and has served on the Scientific Advisory Board since 2005.
Investor Verification Checklist
- Confirm Dr. Ben Wu's current status and tenure on the Board of Directors.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains none.
- Verify if Dr. Wu's appointment triggers any changes in executive compensation or related party transaction disclosures.